Expert Panel Recommendations for the Identification and Management of Hyperkalemia and Role of Patiromer in Patients with Chronic Kidney Disease and Heart Failure-Reference-Cited by-同舟云学术

Expert Panel Recommendations for the Identification and Management of Hyperkalemia and Role of Patiromer in Patients with Chronic Kidney Disease and Heart Failure

Published:2017-04 Issue:4-a Suppl Volume:23 Page:S10-S19
ISSN:2376-0540
Container-title:Journal of Managed Care & Specialty Pharmacy
language:en
Short-container-title:JMCP

Author:

Rafique Zubaid¹,Weir Matthew R.²,Onuigbo Macaulay³,Pitt Bertram⁴,Lafayette Richard⁵,Butler Javed⁶,Lopes Maria⁷,Farnum Carolyn⁷,Peacock W. Frank¹

Affiliation:

1. Baylor College of Medicine, Texas Medical Center, Houston.

2. University of Maryland School of Medicine, Baltimore

3. Mayo Clinic Health System, Eau Claire, Wisconsin, and Mayo Clinic, Rochester, Minnesota

4. University of Michigan School of Medicine, Ann Arbor

5. Stanford University Medical Center, Stanford, California

6. Stony Brook University, Stony Brook, New York.

7. Magellan Rx Management, Newport, Rhode Island.

Publisher

Academy of Managed Care Pharmacy

Subject

Health Policy,Pharmaceutical Science,Pharmacy

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Consensus statement on the management of hyperkalaemia—An Asia–Pacific perspective;Nephrology;2024-02-25

2. Hiperkalemia crónica, diagnóstico y manejo. Consenso colombiano;Archivos de Cardiología de México;2023-11-06

3. Difficulties in electrocardiographic diagnosis of hyperkalemia and acute coronary syndrome: clinical case;CardioSomatics;2023-08-09

4. Acute flaccid paralysis due to multifactorial hyperkalaemia;BMJ Case Reports;2023-06

5. Patiromer utility as an adjunct treatment in patients needing urgent hyperkalaemia management (PLATINUM): design of a multicentre, randomised, double-blind, placebo-controlled, parallel-group study;BMJ Open;2023-06